ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

iCoreConnect Announces New Version of Its iCoreExchange Encrypted HIPAA Email and Referral Network

The Upgrade Provides Significant Enhancements to the Popular Product’s Features and Functionality

OCOEE, FL - (NewMediaWire) - September 06, 2023 -  iCoreConnect, Inc. (Nasdaq: ICCT)(“iCore” or the “Company”), a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise and healthcare workflow platform, today announced the release of iCoreExchange V6.0, a solution that further enhances the features and functionality of its popular HIPAA compliant email product.

The enhanced features of iCoreExchange V6.0 include a modern and intuitive user interface, Google Chrome notifications, simplified Two-Factor Authentication (2FA), and a new Compose window for rapid email writing. iCoreConnect continues to value and leverage direct feedback from users to upgrade its products, providing customers with effective solutions to address the ever-evolving challenges inhibiting workflow efficiency.

Longstanding benefits of iCoreExchange include:

      An intuitive interface that looks and feels just like common email platforms

      The ability to communicate with anyone in or out of the exchange network

      A dashboard that allows users to integrate all existing email accounts for a single-sign-on experience

      Access to a powerful referral network of doctors throughout the nation

      No threats from spam or phishing; full audit compliance

      The ability to transfer any file sizes that are otherwise blocked by commercial email providers

      U.S.-based support system

Robert McDermott, President and CEO of iCoreConnect, stated, “The upgrade to iCoreExchange V6.0 addresses feedback received from our customers, who desired enhanced features and functionality to optimize the user experience. User feedback from our subscribers is vital to the continued refinement of our products to meet the current industry needs.  We look forward to ongoing collaboration as we continue to develop cutting-edge products and solutions for our customers.”

Muralidar Chakravarthi, CTO of iCoreConnect, concluded, "This upgrade ushers in a multitude of enhancements to the platform, encompassing improved performance, usability, and security features. Particularly noteworthy is the implementation of a much more streamlined mechanism for multi-factor authentication, contributing to an overall more secure user experience."

iCoreExchange provides a secure, HIPAA-compliant SaaS email solution using the direct protocol that allows doctors to send and receive secure emails with attachments to and from other healthcare professionals in the network. iCoreExchange also provides a secure email mechanism to communicate with users outside the exchange e.g., patients and referrals. Users have the ability to build a community, access other communities, and increase referrals and collaboration. Icoreconnect.com/icoreexchange

About iCoreConnect, Inc. (Nasdaq: ICCT)

iCoreConnect, Inc. is a cloud-based software and technology company focused on increasing workflow productivity and practice profitability through its enterprise and healthcare workflow platform of applications and services. iCoreConnect is most notably known for its innovation in solving healthcare business problems. iCoreConnect’s philosophy places a high value on customer feedback, allowing iCoreConnect to respond to the market’s needs. iCoreConnect touts a platform of 16 SaaS enterprise solutions and more than 100 product endorsements with state or regional healthcare associations across the United States.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company’s ability to successfully roll out iCoreExchange V6.0. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the “Risk Factors” section in the Company’s Form S-4 filed with the Securities and Exchange Commission (“SEC”) on June 21, 2023, and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contacts:

Davis Snyder or Nick Nelson

ICCT@alpha-ir.com

312-445-2870

 

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.25
+2.28 (1.00%)
AAPL  269.00
+0.19 (0.07%)
AMD  258.01
-1.66 (-0.64%)
BAC  52.87
-0.15 (-0.28%)
GOOG  268.43
-1.50 (-0.56%)
META  751.44
+0.62 (0.08%)
MSFT  542.07
+10.55 (1.98%)
NVDA  201.03
+9.54 (4.98%)
ORCL  280.83
-0.57 (-0.20%)
TSLA  460.55
+8.13 (1.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.